DNAmito Inc. to Integrate Genomics-Based Personalized Analysis With Varian’s Oncology Care Management Software Platform to Optimize Physician’s Decisions Regarding Radiation Treatment for Cancer
PALO ALTO, Calif., Nov. 16, 2017 /PRNewswire/ — DNAmito, Inc. (Palo Alto, CA) and Varian Medical Systems (NYSE: VAR) announced today a development and OEM agreement to integrate Prodecis into Varian’s 360 Oncology™ care management software platform.
Prodecis will enable 360 Oncology to deliver genomics-based evidence to help clinicians make more informed decisions.
Prodecis is a clinical-grade multifactor decision support system integrating all currently available patient data to allow personalized treatment of cancer. The predictive models based on toxicity, tumor control, quality of life and cost effectiveness, enhance the ability of 360 Oncology to provide the information needed by a clinician to recommend the optimal individualized treatment for each patient.
“Varian is committed to delivering cutting-edge technology that helps ensure clinical decisions are made with the most complete information available for the best cancer outcomes. Varian is leveraging 360 Oncology as an enabling platform to allow its partners, such as DNAmito, to provide its value-added services to cancer treatment professionals,” said Sukhveer Singh, vice president of Oncology Continuum Solutions at Varian Medical Systems.
Dr. Philippe Lambin, co-inventor and chief scientific advisor for DNAmito, added: “We are excited to be selected by one of the world leaders in radiation oncology for our multifactorial decision support system for cancer treatment. We have shown that it is an essential tool for precision medicine. Prodecis when combined with 360 Oncology can integrate various types of medical data available as well as proprietary gene signatures to support the choice of the best treatment.”
The science behind the DNAmito platform is based on research from Maastricht University. DNAmito solutions provide genomics-based personalized analysis for radio-sensitivity to optimize radiation treatment for cancer.